Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa

  Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients
                          with Epidermolysis Bullosa

  PR Newswire

  SAN DIEGO, February 8, 2013

SAN DIEGO, February 8, 2013 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), today announced the initiation of a Phase
3 study designed to evaluate the efficacy and safety of ABH001, its dermal
substitute therapy, for the treatment of non-healing wounds in patients with
Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin
to manifest at birth or early childhood and occur in approximately 19 per 1
million live births in the US. ^[i] 

"People affected by EB suffer skin blisters and almost constant, acute pain
and scarring," said the study's Principal Investigator, H. Alan Arbuckle, MD,
Section Head Pediatric Dermatology Kaiser Permanente Colorado, Wound Care
Consultant, Epidermolysis Bullosa Center of Excellence, The Children's
Hospital, Aurora Colorado. "The current standard of care is daily wound care,
bandaging and pain management. I am excited to be involved in testing the
efficacy and safety of ABH001 as a potential treatment option for these

ABH001 for EB has been granted an orphan drug designation in the US and EU,
and has also received Fast Track designation from the US Food and Drug
Administration (FDA), which is aimed at facilitating the development and
expediting the review of drugs and biologics that fill an unmet medical need.
In addition, the European Medicines Agency's Pediatric Committee has agreed on
a pediatric investigation plan for ABH001 for the treatment of EB.

The new Phase 3 study is a multi-site, prospective, randomized, open-label,
intra-subject controlled trial evaluating the efficacy and safety of ABH001 to
initiate healing and reduce the wound surface area of selected stalled,
chronic cutaneous wounds associated with generalized EB. Approximately 20
subjects with generalized EB aged three years and older are planned to enroll
in the trial, which is targeted to be conducted in 10 to 15 sites across the
US, Europe and Canada. The study will comprise ABH001 applications sufficient
to cover the surface area of the wound, applied topically every 4 weeks with
protocol-specified dressings until healed or for up to 24 weeks.

"We are excited that Shire Regenerative Medicine has launched this trial,"
said Brett Kopelan, Executive Director of the Dystrophic EB Research
Association of America (DebRA ) and father to a 5-year-old girl with recessive
dystrophic EB. "While there is currently no cure for EB, I am encouraged that
ABH001 is…targeting the chronic wounds that are the hallmark of this
disease.I applaud Shire for pushing this forward and look forward to working
closely with them as the trial progresses." 

"We are very eager to begin evaluating ABH001 as a potential wound treatment
option for people with EB. We believe it has the potential to initiate and
continue wound healing in this patient population," said Jeff Jonas, MD,
President of Shire Regenerative Medicine. "We are committed to developing
regenerative medicine solutions that enable people with life-altering
conditions to lead better lives, and are encouraged by the fast track and
orphan drug designations we have received to further develop this potential
therapy for people, most often young children, suffering from this devastating

Shire is also developing an intravenous protein replacement therapy for the
treatment of dystrophic EB, which the company's Human Genetic Therapies
business recently acquired from Lotus Tissue Repair, Inc. Initiation of this
pivotal trial of ABH001 for patients with EB further demonstrates Shire's
commitment to developing a portfolio of products targeted toward patients who
suffer from this disease.

ABH001 is comprised of allogenic neonatal dermal fibroblasts seeded on a
poly(glycolide-co-L-lactide) scaffold, and is currently approved and marketed
in the United States as a Class III medical device under the trade name
Dermagraft ^® for the treatment of diabetic foot ulcers.

About Epidermolysis Bullosa (EB)

Epidermolysis Bullosa is a family of genetic skin fragility disorders,
primarily clinically characterized by blistering of the skin in response to
friction or minor trauma. Although genetically and phenotypically
heterogeneous, the common factor in all EB patients is the near constant
presence of skin erosions and wounds. Severe forms of EB cause patients to
live with constant pain and scarring, and may be fatal.

About ABH001

ABH001 is a tissue-engineered, human fibroblast-derived dermal substitute
generated by culturing human neonatal dermal fibroblasts onto a bioabsorbable
polyglactin (PGLLA) mesh scaffold. The fibroblasts, which are grown onto the
PGLLA mesh, secrete dermal collagen, other extracellular matrix proteins,
growth factors, and cytokines, creating a three-dimensional human tissue
containing metabolically active living cells. The final product consists of a
well-developed dermal matrix and evenly dispersed neonatal dermal fibroblasts.

About Dermagraft

Dermagraft is indicated for use in the treatment of full-thickness diabetic
foot ulcers greater than six weeks duration, which extend through the dermis,
but without tendon, muscle, joint capsule, or bone exposure. Dermagraft should
be used in conjunction with standard wound care regimens and in patients that
have adequate blood supply to the involved foot. Dermagraft is contraindicated
for use in ulcers that have signs of clinical infection or in ulcers with
sinus tracts. Dermagraft is contraindicated in patients with known
hypersensitivity to bovine products, as it may contain trace amounts of bovine
proteins from the manufacturing medium and storage solution.


Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide
healthcare in the areas of:

  *Behavioral Health and Gastro Intestinal conditions
  *Rare Diseases
  *Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for
patients, physicians, policymakers, payors and our shareholders.


Statements included in this announcement that are not historical facts are
forward-looking statements. Forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event
such risks or uncertainties materialize, Shire's results could be materially
adversely affected. The risks and uncertainties include, but are not limited
to, that:

  *Shire's products may not be a commercial success;
  *revenues from ADDERALL XR are subject to generic erosion;
  *the failure to obtain and maintain reimbursement, or an adequate level of
    reimbursement, by third-party payors in a timely manner for Shire's
    products may impact future revenues and earnings;
  *Shire relies on a single source for manufacture of certain of its products
    and a disruption to the supply chain for those products may result in
    Shire being unable to continue marketing or developing a product or may
    result in Shire being unable to do so on a commercially viable basis;
  *Shire uses third party manufacturers to manufacture many of its products
    and is reliant upon third party contractors for certain goods and
    services, and any inability of these third party manufacturers to
    manufacture products, or any failure of these third party contractors to
    provide these goods and services, in each case in accordance with its
    respective contractual obligations, could adversely affect Shire's ability
    to manage its manufacturing processes or to operate its business;
  *the development, approval and manufacturing of Shire's products is subject
    to extensive oversight by various regulatory agencies and regulatory
    approvals or interventions associated with changes to manufacturing sites,
    ingredients or manufacturing processes could lead to significant delays,
    increase in operating costs, lost product sales, an interruption of
    research activities or the delay of new product launches;
  *the actions of certain customers could affect Shire 's ability to sell or
    market products profitably and fluctuations in buying or distribution
    patterns by such customers could adversely impact Shire's revenues,
    financial conditions or results of operations;
  *investigations or enforcement action by regulatory authorities or law
    enforcement agencies relating to Shire's activities in the highly
    regulated markets in which it operates may result in the distraction of
    senior management, significant legal costs and the payment of substantial
    compensation or fines;
  *adverse outcomes in legal matters and other disputes, including Shire's
    ability to obtain, maintain, enforce and defend patents and other
    intellectual property rights required for its business, could have a
    material adverse effect on Shire's revenues, financial condition or
    results of operations;

and other risks and uncertainties detailed from time to time in Shire's
filings with the U.S. Securities and Exchange Commission, including its most
recent Annual Report on Form 10-K.

i. Fine J-D, Johnson LB, Suchindran C, Gedde-DahI T (1999e) The Epidemiology
of Inherited Epidermolysis Bullosa: Findings in U.S., Canadian, and European
Study Populations. In: Epidermolysis bullosa : clinical, epidemiologic, and
laboratory advances, and the findings of the National Epidermolysis Bullosa
Registry(Fine, J.-D. and National Epidermolysis Bullosa Registry (U.S.), eds),
pp 101-113 Baltimore: Johns Hopkins University Press.

For further information please contact:

Investor Relations

Eric Rojas, , +1-781-482-0999

Sarah Elton-Farr, , +44-1256-894157


Jessica Mann (Corporate), , +44-1256-894-280

Lindsey Hart (Regenerative Medicine), , +1-206-335-0114
Press spacebar to pause and continue. Press esc to stop.